# Travere Therapeutics share price today (Travere Therapeutics, Inc., TVTX)

> Travere Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TVTX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/tvtx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $48.87 (+51.1% in a year)
- Revenue (Jun 2026): $170 M (+48.2% on a year ago)
- Profit (Jun 2026): −$34.8 M
- Operating margin: 2.3% (+13.4 points on a year ago)

Biggest thing to watch: the price has already been rising for 62 weeks, so timing is the risk more than the business. ## What is the Travere Therapeutics share price today? Travere Therapeutics, Inc.'s share price was $48.87 at the close on 5 November 2026. It has been rising for 62 weeks. That is 3.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $27 and $66, and at that close it sat 56% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 7 weeks running. Over the last 10 years the share price moved +162% while the S&P 500 moved +245%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Travere Therapeutics pay? Travere Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Travere Therapeutics on? Travere Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Travere Therapeutics profitable? Travere Therapeutics, Inc. posted a net loss of $34.8 M in the Jun 2026 quarter. The full FY25 year was a loss of $25.5 M. That loss is 20.5% of the quarter's revenue. The same quarter a year earlier lost $12.8 M. 9 of the last 12 reported quarters were loss-making. ## How much revenue does Travere Therapeutics make, and is it growing? Travere Therapeutics, Inc. reported $170 M of revenue in the Jun 2026 quarter, +48.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 38.9% a year on average. The last full year, FY25, came in at $491 M. The last four reported quarters add to $591 M. FY25 revenue was $491 M, +110.5% on the year before. Recent pace: the last four quarters grew +84.8% on average, against 38.9% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +77.1%, against +82.4% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Travere Therapeutics keep? Travere Therapeutics, Inc.'s operating margin was 2.3% in the Jun 2026 quarter, 13.4 percentage points higher than the same quarter a year ago. Across 5 years it has been between −292.2% and −12.8%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +13.4 percentage points on the year while gross margin changed +15.4 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Travere Therapeutics' profit turning into cash? Travere Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $37.8 M of operating cash against −$25.5 M of profit. After null of spending on assets, $37.8 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Travere Therapeutics' cash go? Travere Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.1 M on assets over the last 1 years. Averaged over those years that is 1.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $5.1 M over the last 1 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Travere Therapeutics' P/E ratio, and how does it compare with its own history? Travere Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Travere Therapeutics, Inc. at 9.6× its FY25 revenue of $491 M. The P/E comes back here once profit turns positive. ## Is the Travere Therapeutics business getting better or worse? Travere Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Travere Therapeutics earn on its capital? Travere Therapeutics, Inc. earned a ROE of −22% in FY25. That is up from a low of −650% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −8,414%, a number that says nothing useful about the business. It comes from a −5.2% net margin and 0.81× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −5.2% net margin × 0.81× asset turnover × 5.27× leverage (assets divided by equity) ≈ −22.2% on equity. The margin does its share; borrowing is a big part of it. ## Does Travere Therapeutics have too much debt? Travere Therapeutics, Inc. has total debt of $617 M against shareholder equity of $24.5 M as of Jun 2026, so its debt is 25.16× its equity. Year by year, that ratio went from 0.87 in FY21 to 2.86 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Travere Therapeutics shareholding pattern? 11.7% of Travere Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Travere Therapeutics from balance-sheet trouble? For Travere Therapeutics, Inc., the Z-score is 1.47. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.47 is inside the danger zone, so the balance sheet is a real risk. ## How does Travere Therapeutics rank in its industry? There is no score against its industry: Travere Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Travere Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Travere Therapeutics in size? Travere Therapeutics is the 45th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Scholar Rock Holding Corporation, PTC Therapeutics, Inc. and CRISPR Therapeutics AG. Just below it: Dianthus Therapeutics, Inc., Legend Biotech Corporation and Catalyst Pharmaceuticals, Inc. ### Biotechnology companies close in size

1. [Scholar Rock Holding Corporation](https://www.sectoralpha.in/us/stocks/srrk) $5.5 billion
2. [PTC Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptct) $5.5 billion
3. [CRISPR Therapeutics AG](https://www.sectoralpha.in/us/stocks/crsp) $4.7 billion
4. Travere Therapeutics, Inc. $4.7 billion
5. [Dianthus Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/dnth) $4.6 billion
6. [Legend Biotech Corporation](https://www.sectoralpha.in/us/stocks/legn) $4.4 billion
7. [Catalyst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/cprx) $3.9 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Methanex Corporation](https://www.sectoralpha.in/us/stocks/meoh) $5.1 billion · Chemicals
2. [NorthWestern Energy Group, Inc.](https://www.sectoralpha.in/us/stocks/nwe) $5 billion · Utilities - Regulated Electric
3. Travere Therapeutics, Inc. $5 billion
4. [Colliers International Group Inc.](https://www.sectoralpha.in/us/stocks/cigi) $5 billion · Real Estate Services
5. [Applied Digital Corporation](https://www.sectoralpha.in/us/stocks/apld) $5 billion · Information Technology Services

## What else do people ask about Travere Therapeutics? ### What were Travere Therapeutics's latest quarterly results? Travere Therapeutics, Inc. reported revenue of $170 M and a net loss of $34.8 M for the Jun 2026 quarter. Earnings per share were −$0.37. The operating margin was 2.3%, 13.4 percentage points higher than a year earlier (as of 5 November 2026). ### What is Travere Therapeutics's market cap? Travere Therapeutics, Inc.'s market capitalisation is $4.7 B at a stock price of $48.87. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Travere Therapeutics performing? Travere Therapeutics, Inc.'s share price has been rising for 62 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 7 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Travere Therapeutics's stock price go up? This page does not forecast Travere Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $48.87, and it has been rising for 62 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Travere Therapeutics have too much debt? Yes, Travere Therapeutics, Inc. has a lot of debt: its debt is 27.28× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### Where is Travere Therapeutics in its business cycle? Travere Therapeutics, Inc.'s FY25 operating margin was −12.8%, against a 5-year range of −292.2% to −12.8%: the middle of its own range, neither a peak nor a low. The latest quarter was 2.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Travere Therapeutics story? Biggest thing to watch: the price has already been rising for 62 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Travere Therapeutics a stock worth studying right now? What the numbers show: Travere Therapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.